A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome.
Latest Information Update: 16 May 2013
Price :
$35 *
At a glance
- Drugs Atopaxar (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 30 Aug 2010 Results have been published in the European Heart Journal.
- 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.